Sinco Pharmaceuticals Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Sinco Pharmaceuticals Holdings şirketinin toplam hissedar öz sermayesi CN¥644.7M ve toplam borcu CN¥327.3M olup, bu da borç-öz sermaye oranını 50.8% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥1.8B ve CN¥1.2B dir. Sinco Pharmaceuticals Holdings 'in FAVÖK'ü CN¥131.5M faiz karşılama oranı 158.6 dur. Şirketin CN¥282.0M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

50.8%

Borç/özkaynak oranı

CN¥327.33m

Borç

Faiz karşılama oranı	158.6x
Nakit	CN¥282.01m
Eşitlik	CN¥644.70m
Toplam yükümlülükler	CN¥1.17b
Toplam varlıklar	CN¥1.82b

Son finansal sağlık güncellemeleri

Recent updates

Lacklustre Performance Is Driving Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 26% Price Drop

Nov 20

What Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 32% Share Price Gain Is Not Telling You

Oct 04

Risks To Shareholder Returns Are Elevated At These Prices For Sinco Pharmaceuticals Holdings Limited (HKG:6833)

Aug 16

Some Investors May Be Willing To Look Past Sinco Pharmaceuticals Holdings' (HKG:6833) Soft Earnings

Apr 02

Sinco Pharmaceuticals Holdings Limited (HKG:6833) Might Not Be As Mispriced As It Looks

Mar 08

Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

Nov 07

A Look At The Intrinsic Value Of Sinco Pharmaceuticals Holdings Limited (HKG:6833)

Jun 26

Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

May 30

Sinco Pharmaceuticals Holdings (HKG:6833) Has A Pretty Healthy Balance Sheet

Oct 26

Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Might Deserve Your Attention Today

Feb 04

I Ran A Stock Scan For Earnings Growth And Sinco Pharmaceuticals Holdings (HKG:6833) Passed With Ease

Oct 25

Little Excitement Around Sinco Pharmaceuticals Holdings Limited's (HKG:6833) Earnings

Jun 10

Sinco Pharmaceuticals Holdings (HKG:6833) Could Easily Take On More Debt

May 24

Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Is An Interesting Stock

Apr 20

We're Not So Sure You Should Rely on Sinco Pharmaceuticals Holdings' (HKG:6833) Statutory Earnings

Feb 16

How Much Did Sinco Pharmaceuticals Holdings'(HKG:6833) Shareholders Earn From Share Price Movements Over The Last Three Years?

Jan 11

Should You Be Excited About Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 51% Return On Equity?

Dec 07

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 6833 'nin kısa vadeli varlıkları ( CN¥1.3B ) kısa vadeli yükümlülüklerini ( CN¥1.1B ) aşıyor.

Uzun Vadeli Yükümlülükler: 6833 şirketinin kısa vadeli varlıkları ( CN¥1.3B ) uzun vadeli yükümlülüklerini ( CN¥29.9M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 6833 'nin net borç/öz sermaye oranı ( 7% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: 6833 'nin borç/öz sermaye oranı son 5 yılda 369.6% seviyesinden 50.8% seviyesine düştü.

Borç Kapsamı: 6833 'nin işletme nakit akışı negatif olduğundan borçlar iyi karşılanamıyor.

Faiz Kapsamı: 6833 'in borcuna ilişkin faiz ödemeleri EBIT ( 158.6 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Sinco Pharmaceuticals Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

Sinco Pharmaceuticals Holdings (HKG:6833) Has A Pretty Healthy Balance Sheet

Sinco Pharmaceuticals Holdings (HKG:6833) Could Easily Take On More Debt

Recent updates

Lacklustre Performance Is Driving Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 26% Price Drop

What Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 32% Share Price Gain Is Not Telling You

First half 2024 earnings released: EPS: CN¥0.012 (vs CN¥0.01 in 1H 2023)

Risks To Shareholder Returns Are Elevated At These Prices For Sinco Pharmaceuticals Holdings Limited (HKG:6833)

Sinco Pharmaceuticals Holdings Limited to Report Q2, 2024 Results on Aug 28, 2024

Sinco Pharmaceuticals Holdings Limited, Annual General Meeting, May 16, 2024

Some Investors May Be Willing To Look Past Sinco Pharmaceuticals Holdings' (HKG:6833) Soft Earnings

Dividend reduced to HK$0.0039

Sinco Pharmaceuticals Holdings Limited Proposes Final Cash Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024

Sinco Pharmaceuticals Holdings Limited Resignation of Li Kin Wai as Joint Company Secretary and Appointment of Peng Yunlu as Executive Director

Sinco Pharmaceuticals Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Now 20% overvalued

Sinco Pharmaceuticals Holdings Limited (HKG:6833) Might Not Be As Mispriced As It Looks

Now 20% overvalued

Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

New minor risk - Share price stability

First half 2023 earnings released: EPS: CN¥0.01 (vs CN¥0.03 in 1H 2022)

Now 20% undervalued after recent price drop

Sinco Pharmaceuticals Holdings Limited to Report Q2, 2023 Results on Aug 30, 2023

A Look At The Intrinsic Value Of Sinco Pharmaceuticals Holdings Limited (HKG:6833)

Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

Full year 2022 earnings released: EPS: CN¥0.034 (vs CN¥0.078 in FY 2021)

Sinco Pharmaceuticals Holdings (HKG:6833) Has A Pretty Healthy Balance Sheet

First half 2022 earnings released: EPS: CN¥0.03 (vs CN¥0.044 in 1H 2021)

Sinco Pharmaceuticals Holdings Limited to Report First Half, 2022 Results on Aug 31, 2022

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS: CN¥0.078 (vs CN¥0.07 in FY 2020)

Sinco Pharmaceuticals Holdings Limited, Annual General Meeting, May 13, 2022

Investor sentiment improved over the past week

Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Might Deserve Your Attention Today

Sinco Pharmaceuticals Holdings Limited (SEHK:6833) entered into a letter of interest to acquire Deyang Demei Medical Aesthetic Clinic from Jiang Biao, Jiang Min and Jiang Jun.

Investor sentiment deteriorated over the past week

Sinco Pharmaceuticals Holdings Limited has completed a Follow-on Equity Offering in the amount of HKD 206.4 million.

Investor sentiment improved over the past week

Investor sentiment improved over the past week

I Ran A Stock Scan For Earnings Growth And Sinco Pharmaceuticals Holdings (HKG:6833) Passed With Ease

First half 2021 earnings released: EPS CN¥0.044 (vs CN¥0.019 in 1H 2020)

Little Excitement Around Sinco Pharmaceuticals Holdings Limited's (HKG:6833) Earnings

Sinco Pharmaceuticals Holdings (HKG:6833) Could Easily Take On More Debt

Full year 2020 earnings released: EPS CN¥0.07 (vs CN¥0.014 in FY 2019)

Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Is An Interesting Stock

Joint Company Secretary has left the company

Full year 2020 earnings released: EPS CN¥0.07 (vs CN¥0.014 in FY 2019)

Sinco Pharmaceuticals Holdings Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day high: HK$0.32

We're Not So Sure You Should Rely on Sinco Pharmaceuticals Holdings' (HKG:6833) Statutory Earnings

Sinco Pharmaceuticals Holdings Limited Announces Management Changes

How Much Did Sinco Pharmaceuticals Holdings'(HKG:6833) Shareholders Earn From Share Price Movements Over The Last Three Years?

Sinco Pharmaceuticals Holdings Limited Announces Board Changes

New 90-day low: HK$0.26

Should You Be Excited About Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 51% Return On Equity?

Sinco Pharmaceuticals Holdings Limited Appoints Jin Min as Co-Chief Executive Officer

New 90-day high - HK$0.30

Sinco Pharmaceuticals Holdings Limited to Report Q2, 2020 Results on Aug 28, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin